News | March 14, 2013

FDA Approves Jubilant HollisterStier as New Manufacturer for Definity Ultrasound Contrast Agent

March 14, 2013 — Lantheus Medical Imaging Inc. announced the U.S. Food and Drug Administration (FDA) has granted approval of a supplemental new drug application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its ultrasound imaging agent, Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension.

Definity is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

“FDA approval of JHS as a new manufacturer for Definity is a major step forward in providing consistent and reliable supply to our customers,” said Jeff Bailey, Lantheus president and CEO. “Supply chain diversification is a significant priority for the company as we work to ensure long-term product availability to meet market demand. We remain dedicated to providing the highest quality products to our customers and the patients they serve.”

Definity is currently manufactured by Ben Venue Laboratories (BVL) in Bedford, Ohio. In August 2011, BVL announced it would exit the contract manufacturing services business over the next several years. In February 2012, Lantheus entered into a manufacturing and supply agreement with JHS for the manufacture of Definity. Additionally, the company entered into similar agreements with JHS in May 2012 for the manufacture and supply of Cardiolite and Neurolite, which are also currently manufactured by BVL. JHS will become Lantheus’s lead supplier of Definity, as well as Cardiolite and Neurolite, as BVL transitions out of the contract manufacturing services business. Lantheus is currently working to secure additional alternative suppliers for its key products as part of its ongoing supply chain diversification strategy.

For more information: www.definityimaging.com

Related Content

Iodine-based CT contrast with ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs. It is not clear that contrast caused contract induced nephrapathy (CIN), also referred to as acute kidney injury (AKI) or contrast-associated acute kidney injury (CAAKI),

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

Feature | Contrast Media | May 31, 2019 | Dave Fornell, Editor
Iodine-based contrast agents used in c
DyeMINISH Multi-center Global Patient Registry Launched
News | Contrast Media | May 09, 2019
Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...